Vaginal cancer treated with curative radiotherapy with or without concomitant chemotherapy

• Verfasst von: Meixner, Eva [VerfasserIn]
• Verfasst von: Arians, Nathalie [VerfasserIn]
• Verfasst von: Bougatf, Nina [VerfasserIn]
• Verfasst von: Hoeltgen, Line [VerfasserIn]
• Verfasst von: König, Laila [VerfasserIn]
• Verfasst von: Lang, Kristin [VerfasserIn]
• Verfasst von: Domschke, Christoph [VerfasserIn]
• Verfasst von: Wallwiener, Markus [VerfasserIn]
• Verfasst von: Lischalk, Jonathan W. [VerfasserIn]
• Verfasst von: Kommoss, Felix [VerfasserIn]
• Verfasst von: Debus, Jürgen [VerfasserIn]
• Verfasst von: Hörner-Rieber, Juliane [VerfasserIn]
• Titel: Vaginal cancer treated with curative radiotherapy with or without concomitant chemotherapy
• Titelzusatz: oncologic outcomes and prognostic factors
• Verf.angabe: Eva Meixner, Nathalie Arians, Nina Bougatf, Line Hoeltgen, Laila König, Kristin Lang, Christoph Domschke, Markus Wallwiener, Jonathan W. Lischalk, Felix K.F. Kommoss, Jürgen Debus and Juliane Hörner-Rieber
• Jahr: 2023
• Umfang: 9 S.
• Fussnoten: First published online November 1, 2021 ; Gesehen am 06.02.2023
• Titel Quelle: Enthalten in: Tumori journal
• Ort Quelle: Thousand Oaks, Calif. : Sage Publishing, 1947
• Jahr Quelle: 2023
• Band/Heft Quelle: 109(2023), 1, Seite 112-120
• ISSN Quelle: 2038-2529
• DOI: doi:10.1177/03008916211056369
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1833331478
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

Background:Vaginal cancer is a rare disease for which prospective randomized trials do not exist. We aimed to assess survival outcomes, patterns of recurrence, prognostic factors, and toxicity in the curative treatment using image-guided radiotherapy (RT).Methods:In this retrospective review, we identified 53 patients who were treated at a single center with external beam radiotherapy and brachytherapy with or without concomitant chemotherapy from 2000 to 2021.Results:With a median follow-up of 64.5 months, the Kaplan-Meier 2-, 5-, and 7-year overall survival (OS) was found to be 74.8%, 62.8%, and 58.9%, respectively. Local and distant control were 67.8%, 65.0%, and 65.0% and 74.4%, 62.6%, and 62.6% at 2, 5, and 7 years, respectively. In univariate Cox proportional hazards ratio analysis, OS was significantly correlated to FIGO stage (hazard ratio [HR] 1.78, p = 0.042), postoperative RT (HR 0.41, p = 0.044), and concomitant chemotherapy (HR 0.31, p = 0.009). Local control rates were superior when an equivalent dose in 2-Gy fractions (EQD2) of ?65 Gy was delivered (HR 0.216, p = 0.028) and with the use of concurrent chemotherapy (HR 0.248, p = 0.011). Not surprisingly, local control was inferior for patients with a higher TNM stage (HR 3.303, p = 0.027). Minimal toxicity was observed with no patients having documentation of high-grade toxicity (CTCAE grade 3+).Conclusion:In treatment of vaginal cancer, high-dose RT in combination with brachytherapy is well tolerated and results in effective local control rates, which significantly improve with an EQD2(α/?=10) ?65 Gy. Multivariate analyses revealed concomitant chemotherapy was a positive prognostic factor for overall and progression-free survival.